<DOC>
	<DOCNO>NCT02253121</DOCNO>
	<brief_summary>Purpose study treat glucocorticoid induce hyperglycemia due glucocorticoid pulse therapy efficacious , safe convenient way . Patients acute exacerbation COPD treat glucocorticoid pulse therapy high risk glucocorticoid induce hyperglycemia ( define know type 2 DM glucose &gt; 10mmol/l admission ) randomize treatment dapagliflozin placebo orally , daily . Percentage time within glucose target range ( 3,9-10 mmol/l ) incidence rate hypoglycemia compare dapagliflozin group placebo group .</brief_summary>
	<brief_title>Glucose Control During Glucocorticoid Therapy Acute Exacerbation Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description>Rationale : Patients hospitalize COPD exacerbation treat high dose glucocorticoid , frequently develop hyperglycaemia . Currently , slide scale insulin often use bridge episode . However , slide scale insulin patient unfriendly , reduce glycaemic excursion glycaemic variability . In contrast , pharmacologic inhibition sodium glucose transporter-2 ( SGLT-2 ) give oral agent likely result good glucose control low risk hypoglycaemia Objective : glucose control safety ( risk hypoglycaemia ) . Secondary objective patient satisfaction , safety outcome parameter glucose control Study design : Double-blind placebo control intervention study Study population : Patients hospitalize exacerbation chronic obstructive lung disease treat high dose glucocorticoid . Intervention : One group receive daily 10mg tablet dapagliflozin group receive daily placebo tablet add prestudy glucose-lowering medication . Both group treat glucose lowering escape medication require . Main study parameters/endpoints : Glucose control measure average time spend within target range patient . Safety measure incidence rate hypoglycaemia study follow-up . Nature extent burden risk associate participation , benefit group relatedness : The burden participation consist extra capillary glucose measurement do 3-4 time daily wear coin size glucose sensor . Furthermore , patient fill treatment satisfaction questionnaire . There extra site visit participant . Dapagliflozin ( experimental group ) carry risk hypoglycaemia , especially patient concomitant therapy insulin sulfonylurea derivative . Patients instructed anticipate , required dosing glucose lower therapy adjust . Furthermore , dapagliflozin carry increase risk urogenital infection , increase haematocrit LDL cholesterol .</detailed_description>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<criteria>Informed consent Hospitalization due AECOPD Treatment ≥30mg prednisone daily equivalent dose glucocorticoid AECOPD An expected duration glucocorticoid treatment 314 day study entry Known type 2 diabetes glucose ≥ 10 mmol/l admission High dose glucocorticoid treatment start ≥7 day study entry Need ICU admission Chronic kidney disease stage G3 ( glomerular filtration rate &lt; 60ml/minute ) Recurrent genital urinary tract infection Current use SGLT2 inhibiting agent Suspected volume depletion Congestive heart failure functional classification NYHA class IV/IV instable heart failure Acute stroke within 2 month inclusion . Recent cardiovascular event : acute coronary syndrome , hospitalisation unstable angina coronary revascularisation within 2 month inclusion Suspected liver disease , confirm AST/ALT &gt; 3x ULN bilirubin &gt; 2.0mg/dl ( 34.2 μmol/l ) serologically proven infection hepatitis B hepatitis C Pregnancy breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>COPD</keyword>
	<keyword>acute exacerbation</keyword>
	<keyword>glucocorticoid therapy</keyword>
	<keyword>hyperglycemia</keyword>
</DOC>